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Introduction {#sec1}
============

The use of stem cell-derived organoids as *in vitro* models to study development and disease has been a major advance in recent years ([@bib26]). Organoids provide an advantage over monolayer cultures due to their complex 3D architecture that better approximates *in vivo* tissues. With regard to the kidney, monolayer cultures have had limited utility for modeling the structure and function of nephrons (the tubular units responsible for filtering the blood and maintaining salt and fluid homeostasis). This is not surprising, given that nephrons are subdivided into functionally distinct portions that act in series to generate the urine. Specifically, the renal corpuscle, containing interdigitating podocytes wrapped around a capillary tuft, generates a plasma ultrafiltrate that travels via the proximal tubule, descending and ascending limbs of the loop of Henle, and more distal segments (distal convoluted tubule, connecting tubule) to the collecting duct ([@bib35]).

Early protocols for converting pluripotent stem cells into renal cells attempted to mimic the developmental signals governing early kidney formation from the intermediate mesoderm. A cocktail of secreted factors including low doses (3--5 μM) of the Wnt agonist CHIR99021 (CHIR) were found to induce intermediate mesoderm-like cells ([@bib31], [@bib25]). However, the major breakthrough in the field was the discovery that higher concentrations of CHIR (8 μM) followed by fibroblast growth factor 9 (FGF9) ([@bib2], [@bib52]), a growth factor required for nephron progenitor growth *in vivo*, was sufficient to induce kidney organoids with a global transcriptional profile similar to first-trimester fetal kidneys ([@bib53]). Subsequent methodologies showed that FGF9 can be substituted for B27, a serum-free supplement used to maintain neurons in cell culture ([@bib15]). In addition, more complex combinations of activin A, bone morphogenetic proteins, and FGF9 have been used to achieve kidney organoid formation ([@bib40], [@bib51]). How these factors induce a kidney program in pluripotent stem cells remains poorly understood, although it has been suggested that high levels of CHIR may mimic the Wnt signals that induce the posterior mesoderm where nephron progenitors arise ([@bib54]). A major drawback of the current protocols is the high cost of the reagents, with FGF9 and B27 being prohibitively expensive, thus severely limiting the large-scale culture of kidney organoids.

Despite commonalties in the factors used to induce kidney organoid formation, the existing protocols differ in their technical details and are overall quite complex. For instance, the method of [@bib51] requires co-culture with spinal cord explants (as a source of Wnt), that of [@bib53] involves repeated CHIR treatments, cell dissociation, and then re-aggregation on transwell filters, while [@bib15] generate epiblast "spheroids" that are cultured in a Matrigel sandwich. How reproducible these protocols are between different pluripotent stem cells lines has been highlighted as a concern ([@bib38], [@bib12]) and as patient-derived and gene-edited induced pluripotent stem cell (iPSC) lines from diverse backgrounds continue to be produced, a protocol with universal utility is highly desirable.

To overcome some of these issues, we have developed a strategy for generating kidney organoids from iPSCs that is simple, robust, and cost-effective, and allows large-scale organoid production. Our method involves the formation of embryoid bodies (EBs) in the presence of CHIR, followed by culture in medium supplemented with "KnockOut Serum Replacement" (KOSR) as a substitute for FGF9. Importantly, this approach is inexpensive and highly efficient, allowing kidney organoids to be grown in spinner flasks. The resulting organoids develop nephrons containing podocytes, proximal and distal tubule segments, presumptive collecting ducts, endothelial cells, and interstitial cells that are comparable with the tissues reported using other methods. Comparison with human fetal kidneys reveals that our organoid nephrons most closely correspond to the late capillary loop stage of differentiation. Prolonged culture of our kidney organoids is associated with an expansion in interstitial cells and their conversion into pro-fibrotic myofibroblasts, suggesting that this may be a new model to study renal fibrosis. We further show that our protocol can robustly generate organoids of equivalent quality from three different iPSC lines without a need for line-specific optimization. Finally, we show that disruption of *HNF1B*, a gene implicated in congenital kidney malformations, results in agenesis of kidney tubules, highlighting the value of our method for the study of human kidney development and birth defects.

Results {#sec2}
=======

A Simple, Cost-Effective Method to Generate Kidney Organoids {#sec2.1}
------------------------------------------------------------

We developed a protocol to differentiate human iPSCs into kidney organoids in large numbers via an EB formation step using CHIR, KOSR, and simple spinner-flask bioreactors ([Figure 1](#fig1){ref-type="fig"}A). Specifically, the initial setup of the assay involves growing iPSC colonies in a monolayer to 40%--50% confluence ([Figure 1](#fig1){ref-type="fig"}B). On day 0, the colonies are enzymatically detached and mechanically fragmented into ∼100-μm sized pieces by pipetting ([Figure 1](#fig1){ref-type="fig"}C), and transferred into ultra-low attachment 6-well plates for suspension culture. A 3-day treatment window with 8 μM CHIR in BPEL (BSA poly(vinyl alcohol) essential lipids) medium ([@bib43], [@bib44]) was found to be sufficient to induce aggregation of the colony fragments into spherical EBs ([Figure 1](#fig1){ref-type="fig"}D). We discovered that culturing the CHIR-induced EBs in DMEM with 15% KOSR ("Stage II" medium) from day 3 onward supported tubule formation that was visible under bright-field microscopy by day 8 ([Figure 1](#fig1){ref-type="fig"}E). Gene expression analysis over the course of days 1--8 suggests that our approach recapitulates the developmental program of mesoderm formation and nephrogenesis, with downregulation of mesodermal genes by day 4 that coincides with a rise in renal progenitor markers ([Figure S1](#mmc1){ref-type="supplementary-material"}A). As spinner-flask bioreactors have been found to improve oxygen and nutrient perfusion ([@bib45], [@bib33]), we transferred the organoids into 125-mL spinner flasks at day 8. We found that spinner-flask culture of kidney organoids allows concurrent growth and maturation of hundreds of organoids containing tubular kidney tissue by day 14 ([Figure 1](#fig1){ref-type="fig"}F). From a single 10-cm plate of iPSCs we can generate approximately 1,000 organoids ([Figure S1](#mmc1){ref-type="supplementary-material"}B). This approach is cost-prohibitive using other existing methods, but is feasible in our method due to the low reagent cost of the KOSR/DMEM medium.Figure 1Derivation of Kidney Organoids from Three iPSC Lines(A) Overview of the protocol.(B) Starting iPSC colonies.(C) iPSC colonies in suspension after dispase digest (mean size 105 ± 37 μm, n = 142).(D) Embryoid bodies.(E and F) Kidney organoids at day 8 (d8) and day 14; formation of tubules is visible on the surface (arrows).(G) H&E-stained organoid sections derived from three independent iPSC lines at days 8 and 14, n ≥ 3 sections.(H) Relationship between organoid size, number, and presence of tubules at day 14 (n = 374 organoids in a single representative assay).(I) Bright-field images of organoids in the \<200, 200--700, and \>700 μm size ranges. The small non-tubular specimens are marked with asterisks; a non-tubular outgrowth is indicated by the arrow.(J--M) Immunofluorescent staining of sections from "small" (\<700 μm) and "large" (\>700 μm) organoids showing apoptotic cells stained for activated CASP3 (green) and the proliferation marker PCNA (red). Asterisk in (K) marks a central region with reduced cellularity. n ≥ 3 sections per antibody. Nuclear counterstain: DAPI.Scale bars, 200 μm (D, E, G, and J--M), 400 μm (C and F), and 500 μm (B and I).

Histological analysis of day-8 and day-14 kidney organoids confirmed the presence of tubular epithelia, interstitial cells, and regions resembling primitive glomeruli ([Figures 1](#fig1){ref-type="fig"}G and [S2](#mmc1){ref-type="supplementary-material"}A). Comparable results were obtained when the protocol was applied to three independently reprogrammed iPSC lines: MANZ-2-2, RiPS, and CRL1502-C32 (herein referred to as C32), and in multiple batches from a single line ([Figure S2](#mmc1){ref-type="supplementary-material"}B), although C32 had more of a propensity to form non-renal outgrowths ([Figure 1](#fig1){ref-type="fig"}G). In terms of efficiency (number of organoids that contain nephron-like structures), we found no major differences between the iPSC lines with kidney organoids comprising 80%--90% of the total number of organoids at day 8 (n = 744/787 for RiPS; n = 469/553 for MANZ-2-2; n = 848/989 for C32; ≥3 independent assays per line). Specimens that did not contain tubular structures were clearly distinguishable using bright-field microscopy, and immunohistological analysis confirmed a lack of renal structures and a large proportion of vimentin^+^ mesenchymal cells ([Figure S3](#mmc1){ref-type="supplementary-material"}). We also found that the average diameter of the organoids gradually increased from day 8 to day 26, consistent with growth occurring during this time frame ([Figure S1](#mmc1){ref-type="supplementary-material"}C).

We next analyzed a representative organoid assay to determine whether there was a correlation between organoid diameter and the presence of tubules at day 14. We found tubules in only ∼40% of the organoids with diameters \<200 μm but in ∼90% of the organoids with diameters ≥200 μm ([Figures 1](#fig1){ref-type="fig"}H and 1I, single representative assay shown). As our protocol involves growing the tissue in suspension, we were able to introduce a simple size filtration step using a 200-μm strainer to eliminate these smaller organoids that were enriched for non-renal tissue. In the organoids remaining after this size selection, tubule formation was highly efficient (96%), although this subset contains organoids that have diameters \>700 μm ([Figures 1](#fig1){ref-type="fig"}I and [S1](#mmc1){ref-type="supplementary-material"}C), possibly due to insufficient fragmentation of the iPSC colonies at day 0 and/or EB fusion. Given that the diffusion of oxygen and nutrients becomes limiting as organoid diameter increases ([@bib19], [@bib58]), we examined whether apoptosis was occurring in day-14 organoids in the 200--700 μm and \>700 μm size ranges using immunostaining for activated caspase-3 (CASP3) on day-14 organoid sections. While few CASP3^+^ cells were found scattered throughout the tissue and around clusters of presumptive podocytes in \<700-μm organoids ([Figure 1](#fig1){ref-type="fig"}J), \>700-μm organoids exhibited a notable loss of cellularity in their cores (asterisk in [Figure 1](#fig1){ref-type="fig"}K) and displayed qualitatively more CASP3^+^ cells throughout the tissue. As a further assessment of organoid viability, we performed immunostaining for the proliferation marker PCNA (proliferating cell nuclear antigen). Proliferating cells were widespread throughout \<700-μm organoids ([Figure 1](#fig1){ref-type="fig"}L) but in \>700-μm organoids, cell division was largely restricted to peripheral regions ([Figure 1](#fig1){ref-type="fig"}M). Together, these observations indicate that large organoids (\>700 μm) are associated with central apoptosis and reduced proliferation, suggesting that they may not be as viable as smaller organoids. Based on this, we incorporated an additional size filtration step using a 500-μm strainer to remove these large organoids.

Kidney Organoids Are Composed of Immature Nephrons {#sec2.2}
--------------------------------------------------

To evaluate nephron differentiation in day-14 organoids we surveyed a range of markers by immunostaining. We identified MEIS1/2/3^+^ interstitial cells and PECAM1/CD31^+^ endothelial cells that were scattered throughout the tissue, although in variable numbers ([Figures 2](#fig2){ref-type="fig"}A and 2B). The endothelial cells were often found in close proximity to primitive glomeruli-like structures, which contained cells that stained for the podocyte marker Wilms\' tumor suppressor 1 (WT1; [Figure 2](#fig2){ref-type="fig"}B). Electron microscopy revealed that the podocytes display an immature appearance at day 14 with areas of broad cell-cell contacts. Culture of the organoids to day 26 resulted in more elaborate cell-cell junctions, resembling the early stages of foot process formation ([Figures 2](#fig2){ref-type="fig"}C--2F).Figure 2Stromal and Glomerular Marker Analysis in Kidney Organoids(A and B) Immunostaining of paraffin sections of day-14 organoids showing (A) MEIS1/2/3^+^ interstitial cells (green) and (B) WT1^+^ podocytes (red) and PECAM1^+^ endothelial cells (green) (n ≥ 3 sections per antibody combination). (C--F) Transmission electron micrograph (TEM) images of podocytes (p) with primitive foot processes (fp) at day 14 (C and D) and more developed foot processes at day 26 (E and F; n ≥ 3 images). Nuclear counterstain: DAPI (A and B).Scale bars, 2 μm (D and F), 5 μm (C and E), and 100 μm (A and B).

In addition to podocytes (which also labeled with NPHS1/Nephrin; [Figure 3](#fig3){ref-type="fig"}A), day-14 organoids contained kidney tubules that were subdivided into proximal segments that stain for *Lotus tetragonolobus* lectin (LTL) and distal portions that label with cadherin-1 (CDH1; [Figure 3](#fig3){ref-type="fig"}A). There was little overlap of LTL and CDH1 except in short stretches at their junction in rare tubules (arrows in [Figure 3](#fig3){ref-type="fig"}A and [Video S1](#mmc2){ref-type="supplementary-material"} of a serial z stack through a whole-mount stained organoid). LTL staining was strong apically in proximal tubule cells but also weakly marked the basolateral surface. As mature proximal tubules are subdivided into S1--S3 domains, we co-stained the organoids for LTL and LRP2/megalin, the latter of which is predominantly expressed in the S1 and S2 segments in mature nephrons ([@bib8]). We found that the staining patterns of LTL and LRP2 fully overlap, indicating that the proximal tubules have not undergone any further subsegmentation at this stage ([Figure 3](#fig3){ref-type="fig"}B). Consistent with this relatively immature state of the proximal tubule, apical microvilli were not readily detected at day 14 and are rudimentary at day 26 by electron microscopy ([Figures 3](#fig3){ref-type="fig"}C and 3C′). Despite these immature features, incubation of the organoids with 10-kDa Rhodamine-labeled dextran for 48 hr resulted in the specific uptake of the dextran into LTL^+^ tubules, indicating that the absorptive function of the proximal tubule is acquired early in nephrogenesis ([Figure 3](#fig3){ref-type="fig"}D).Figure 3Tubular Marker Analysis in Kidney Organoids(A) Paraffin sections of day-14 organoids showing (A) LTL^+^ proximal tubules (green), CDH1^+^ distal tubules and collecting ducts (light blue), and NPHS^+^ podocytes (red).(B) Co-labeling of LTL (green) and LRP2 (red) in proximal tubules.(C and C′) TEM images showing proximal tubules with mitochondria and tight junctional complexes at day 14 (C). Rudimentary microvilli are detected at day 26 (C′).(D) Uptake of 10-kDa dextran-rhodamine (red) into LTL^+^ proximal tubules at day 14 (green; n = 8, representative of three independent differentiations).(E) LTL^+^ proximal tubules (green) and SLC12A1^+^ thick ascending limb segments (red).(F) LRP^+^ proximal tubules (red) and UMOD^+^ thick ascending limb segments (green).(G) SLC12A1^+^ thick ascending limb segments (green) and GATA3^+^ tubules/ducts (red).(H) Co-staining of GATA3 (red) and CALB1 (green) in the collecting duct.(I and I′) TEM images of presumptive collecting ducts at day 14 (I) and day 26 (I′) showing large lumen and tight junctions.(J) Co-staining of PAX2 and LRP2.(K and L) Schematic representations of the segmentation patterns of mature human nephrons (K) and day-14 kidney organoids (L).Arrows indicate junctions between segments. Nuclear counterstain: DAPI (blue in B and E--H, gray in D). lu, lumen; mt, mitochondria; mv, microvilli; n, nucleus; tj, tight junction; v, vesicle. n ≥ 3 sections per antibody combination or TEM images. Scale bars, 2 μm (C and C′), 20 μm (D), 5 μm (I and I′), 100 μm (A, F--H, and J), and 200 μm (B and E).

Video S1. Day-14 Organoids Form Contiguous Nephrons, Related to Figure 3

Next, we explored the identity of the distal portion of the nephron. Morphologically, there was no indication of descending or ascending thin limbs, which form part of the loop of Henle and are positioned between the proximal tubule and the thick ascending limb segment. In agreement with this observation, we found that LTL^+^ cells abut a short segment that stains for SLC12A1 and uromodulin (UMOD), markers expressed by the thick ascending limb ([Figures 3](#fig3){ref-type="fig"}E and 3F; arrows). While we were unable to detect the distal convoluted tubule marker SLC12A3 at this stage, we did find positive staining for GATA3 and calbindin-1 (CALB1), which label the distal convoluted tubule, connecting tubule, and cortical collecting duct in mature adult nephrons ([Figures 3](#fig3){ref-type="fig"}G and 3H; [@bib23], [@bib24], [@bib22], [@bib32], [@bib28]). Interestingly, CALB1 was found to label an internal subdomain of the GATA3^+^ epithelium ([Figure 3](#fig3){ref-type="fig"}H), possibly reflecting the collecting duct based on recent marker analyses in fetal human kidneys ([@bib28]). At the ultrastructural level, presumptive collecting duct and/or distal tubule cells (identified based on their columnar shape and nuclear morphology) display large lumens, well-defined cell junctional complexes, few apical microvilli, and prominent vesicular bodies by day 26 ([Figures 3](#fig3){ref-type="fig"}I and 3I′).

To further assess the differentiation state of day-14 organoid nephrons we examined PAX2, as this transcription factor is downregulated following terminal differentiation of renal epithelial cells ([@bib14]). We found low levels of PAX2 in the proximal tubules but slightly higher levels in the distal nephron/presumptive collecting duct, consistent with an immature level of differentiation ([Figure 3](#fig3){ref-type="fig"}J). Collectively these data show that day-14 kidney organoids, in comparison with mature human nephrons ([Figure 3](#fig3){ref-type="fig"}K), are composed of immature nephrons made up of a primitive glomerulus, an LTL^+^/LRP2^+^ proximal tubule segment most likely attached to an SLC12A1^+^ thick ascending limb segment, and a distal portion most likely comprising one or more nascent distal tubule segments attached to a GATA3^+^/CALB1^+^ collecting duct ([Figure 3](#fig3){ref-type="fig"}L). Organoids derived from three independent iPSC lines displayed similar marker expression ([Figure S4](#mmc1){ref-type="supplementary-material"}).

Extended Organoid Culture Leads to Altered Nephron Differentiation {#sec2.3}
------------------------------------------------------------------

As day-14 organoids are immature, we were interested to find out whether longer culture times would improve differentiation. It has been suggested that co-labeling of LTL and CDH1 is a sign of proximal tubule maturity ([@bib53]). Similar to data reported for other protocols, we also observed tubules that were double positive for LTL and CDH1 in day-26 organoids ([@bib38], [@bib6]). In a subset of these, the double-labeled portions were part of large, abnormally branched structures (arrow in [Figure 4](#fig4){ref-type="fig"}A). To help interpret these results, we investigated the staining pattern of LTL and CDH1 in normal human fetal kidneys at weeks 15--16 of gestation. LTL staining was first apparent in proximal tubules at the early capillary loop stage and became strongly apical (but not basolateral) in proximal tubules that were identified by co-labeling with cubilin ([Figures 4](#fig4){ref-type="fig"}B and 4C). Importantly, CDH1 was only found in the distal portions of the developing nephrons. In more mature fetal nephrons, co-labeling of LTL and CDH1 was detected in some tubules (both apically and basolaterally) but only in the descending limb of the developing loop of Henle in the medulla ([Figure S5](#mmc1){ref-type="supplementary-material"}A). SLC12A3 could not be detected in either early or late capillary loop stage nephrons, consistent with this marker appearing late in human nephrogenesis ([@bib28], [@bib29]).Figure 4Marker Analysis in Day-26 Organoids and Human Kidney Tissue(A) Paraffin section of day-26 kidney organoid showing partial overlap of LTL and CDH1 in tubules. Arrow points to abnormally branched structures.(B and C) Cryosections of human fetal kidney (15--16 weeks gestation) showing LTL^+^ (green; arrow) and CUBULIN^+^ (CUBN; blue) proximal tubules and CDH1 (red) in distal tubules in early (B) and late capillary loop (C) stage nephrons.(D) Paraffin section of an adult human kidney showing non-overlapping staining of LTL (green) and CDH1 (red). n ≥ 3 sections per antibody combination.(E) qPCR analysis for selected markers in the RiPS line and kidney organoids at days 8, 14, and 26. Data are presented as means ± SD from technical triplicates. Nuclear counterstain: DAPI (blue in A, white in B--D).Scale bars, 50 μm (B--D) and 200 μm (A).

To determine whether LTL and CDH1 co-label fully mature proximal tubules, we analyzed human adult kidney tissue. Similar to the fetal findings, LTL and CDH1 staining do not overlap in the cortex or in the loops of Henle but occasional co-labeling is seen in collecting ducts in the inner stripe of the medulla ([Figures 4](#fig4){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}B). Based on these observations, we conclude that endogenous fetal and adult human proximal tubules do not co-label with LTL and CDH1, thus the mixed (LTL^+^/CDH1^+^) identities seen in the organoids may reflect abnormal changes in the tubules following extended culture. Alternatively, this may indicate their conversion to a descending limb-like identity. To further explore whether these changes are associated with altered differentiation, we measured the expression of the lineage markers *NPHS1*, *PECAM1*, *LRP2*, *SLC12A1*, *CALB1*, and *GATA3* in whole organoids at day 8, day 14, and day 26 by qPCR. While most of these markers increased from day 8 to day 14 there was a significant downregulation of *NPHS1* (podocytes), *LRP2* (proximal tubule), *SLC12A1* (thick ascending limb), and *CALB1* (collecting duct) between days 14 and 26 ([Figure 4](#fig4){ref-type="fig"}E). A similar downregulation of these markers was observed in the APEL medium used by [@bib53], suggesting that this was not due to our DMEM/KOSR medium (data not shown). To assess whether the reduction in nephron marker expression at day 26 was associated with compromised tubule function, we performed the fluorescent dextran uptake assay on day-26 organoids and found that proximal tubule absorption was significantly impaired ([Figure S6](#mmc1){ref-type="supplementary-material"}). Taken together, our findings suggest that LTL^+^/CDH1^+^ tubules are unlikely to represent mature proximal tubules and that longer organoid culture beyond day 14 results in a downregulation of marker gene expression, loss of proximal tubule absorptive functionality, and the formation of potentially abnormal LTL^+^/CDH1^+^ tubules. Based on the comparison with human fetal kidneys, our day-14 organoid nephrons approximate late capillary loop stage nephrons.

Organoids at Day 26 Show Fibrosis and Interstitial Cell Expansion {#sec2.4}
-----------------------------------------------------------------

From a histological comparison of day-14 and day-26 organoids, we noticed that the stromal compartment was expanded at day 26 and accompanied by an accumulation of extracellular matrix. As this is reminiscent of fibrosis, we performed Masson\'s trichrome staining on day-14 and day-26 organoids and found that while day-14 organoids show little staining, day-26 organoids display collagen staining around the tubules ([Figure 5](#fig5){ref-type="fig"}A). Immunostaining for α-smooth muscle actin (ACTA2), which labels myofibroblasts responsible for the production of fibrotic tissue, revealed a capsule-like layer around day-14 organoids but no internal labeling. In contrast, day-26 organoids display both capsule-like and interstitial staining, suggesting that between day 14 and day 26 myofibroblasts arise and deposit a collagen-rich extracellular matrix ([Figure 5](#fig5){ref-type="fig"}B). We next compared the MEIS1/2/3^+^ renal interstitial cells at days 14 and 26 and found that this population was qualitatively expanded at day 26 ([Figure 5](#fig5){ref-type="fig"}C). We also noted that between days 14 and 26 there was a change in the pattern of proliferation, with day-14 organoids showing PCNA^+^ cells in both nephrons and interstitial cells ([Figure 1](#fig1){ref-type="fig"}L) whereas in day-26 organoids only rare tubular cells are PCNA^+^ ([Figure 5](#fig5){ref-type="fig"}D). Co-labeling of ACTA2 with MEIS1/2/3 and PCNA in day-26 organoids revealed extensive proliferation of the interstitial cells and a transition to a myofibroblast-like phenotype ([Figures 5](#fig5){ref-type="fig"}E and 5F). In summary, these results suggest that organoid viability is optimal around day 14, when the tissue has small amounts of MEIS1/2/3^+^ interstitial cells and no evidence of fibrosis. After day 14, nephron components of the organoid exhibit reduced proliferation while the interstitium continues to expand with some cells converting to an ACTA2^+^ myofibroblast-like (presumptive pro-fibrotic) state.Figure 5Analysis of Fibrosis and Interstitial Cells in Day-26 Organoids(A) Paraffin sections of day-14 and day-26 organoids stained with Masson\'s trichrome showing collagen deposition at day 26 (blue). n ≥ 3 sections per time point.(B--F) Immunostainings of day-14 and day-26 organoids showing: (B) α-smooth muscle actin (ACTA2)-labeled myofibroblasts (red); (C) MEIS1/2/3^+^ interstitial cells (red) and HNF1B^+^ tubules/ducts (green); (D) PCNA^+^ (proliferating) cells (red); (E and F) Co-labeling of the myofibroblast marker ACTA2 (green) with MEIS1/2/3 (red) in (E) and PCNA (red) in (F). n ≥ 3 sections per antibody combination. Nuclear counterstain: DAPI.Scale bars, 50 μm (F; also applies to E) and 100 μm (A--D).

HNF1B Knockout Organoids as a Model of Congenital Kidney Defects {#sec2.5}
----------------------------------------------------------------

To test the utility of our kidney organoids to study human nephrogenesis, we targeted the *HNF1B* transcription factor gene, which has been shown to play essential roles in tubulogenesis and is implicated in congenital anomalies of the kidney and urinary tract ([@bib41], [@bib42], [@bib17], [@bib34], [@bib10]). Using CRISPR/Cas9 gene editing in MANZ-2-2 iPSCs, we generated three independently derived iPSC lines with biallelic deletions in exon 2 of the *HNF1B* gene. This mutation introduces an early translation stop codon and is predicted to result in a non-functional truncated protein that lacks the DNA binding and transactivation domains ([Figure 6](#fig6){ref-type="fig"}A). The *HNF1B*^−/−^ iPSC lines underwent organoid formation in a similar time frame as the parental line and with equivalent efficiency ([Figures S7](#mmc1){ref-type="supplementary-material"}A--S7D). Bright-field imaging of whole organoids showed that by day 14, *HNF1B*^−/−^ organoids were slightly larger than controls ([Figures 6](#fig6){ref-type="fig"}B and 6C). Expression analysis by qPCR revealed little change in podocyte genes (*NPHS1*, *WT1*) and *GATA3* but a significant downregulation in markers of the proximal tubule (*LRP2*), thick ascending limb (*UMOD*, *SLC12A1*), *CDH1*, and *PAX2*, as well as the HNF1B transcriptional targets *HNF4A* and *PKHD1* (*UMOD* is also a direct target of HNF1B; [Figure 6](#fig6){ref-type="fig"}D). Consistent with these findings, immunostaining of day-14 organoids shows a loss of HNF1B protein (a pan-marker of tubules and collecting duct), LTL, and SLC12A1 in *HNF1B*^−/−^ organoids ([Figures 6](#fig6){ref-type="fig"}E--6J). A similar phenotype was seen as early as day 8 with loss of LTL and HNF1B but normal levels of WT1, PAX2, and GATA3 ([Figures S7](#mmc1){ref-type="supplementary-material"}E and S7F). Together, these findings indicate that disruption of *HNF1B* leads to a failure in the formation of the proximal tubule and thick ascending limb segments, much like that described in the mouse knockout ([@bib17], [@bib34]), with only podocytes and GATA3^+^ distal nephron segments/presumptive collecting ducts forming in the *HNF1B*^−/−^ organoids.Figure 6Characterization of HNF1B^−/−^ Organoids(A) Schematic overview of the CRISPR/Cas9-based strategy to disrupt the *HNF1B* gene. The deletion in exon 2 is marked with red arrowheads, and the Sanger sequencing chromatogram shows how the resulting frameshift causes a premature stop codon.(B and C) Bright-field images of control and *HNF1B*^−/−^ organoids at day 14.(D) qPCR analysis of selected renal markers and known targets of HNF1B (*HNF4A*, *PKHD1*, *UMOD*) in day-14 *HNF1B*^−/−^ kidney organoids compared with controls. Data are presented as means ± SD from technical triplicates.(E--J) Paraffin sections of control and *HNF1B*^−/−^ kidney organoids at day 14 for HNF1B (green), LTL (proximal tubule, green), SLC12A1 (thick ascending limb, green), NPHS1 (podocytes, red), and CDH1 and GATA3 (distal tubule and collecting duct, red). n ≥ 3 sections per antibody combination. Nuclear counterstain: DAPI.Scale bars (B, C, and E--J), 200 μm.

Discussion {#sec3}
==========

Multiple approaches for differentiating pluripotent stem cells into kidney organoids have been reported ([@bib59], [@bib27], [@bib6], [@bib53], [@bib40], [@bib15], [@bib51]). In contrast to most of these methods, we developed an EB-based strategy that generates 3D aggregates of pluripotent stem cells that better mimic the structure of the developing embryo ([@bib18]). Specifically, the EB environment is thought to be conducive to the formation of endogenous morphogenic gradients and fosters cell sorting and self-assembly. Such processes are less efficient in monolayer cultures and this may explain the lack of robustness of other methods ([@bib48]). Not all of the EBs formed by our method give rise to kidney organoids, with smaller aggregates often failing to generate tubular tissue. This observation is in keeping with prior work with EBs in which the "quality" of terminal differentiation is dependent on EB size/cell number ([@bib37], [@bib36]), presumably due to a minimal threshold of cells needed to mimic the developing embryo. The range in EB sizes generated by our approach is probably the result of differences in the sizes of the iPSC colony fragments, which itself is influenced by the starting confluence and the extent of mechanical dissociation. Because our approach is easily scalable, it is possible to generate a large number of EBs. As a result, size exclusion via sieving provides a rapid and labor-efficient way of enriching for organoids with optimal differentiation potential.

A key innovation of our method is the discovery that KOSR can replace more expensive supplements such as B27 used by [@bib15] and FGF2/9 used in other protocols ([@bib53], [@bib40], [@bib27], [@bib51]). At this stage it is not clear how KOSR substitutes for the FGF signaling pathway, which acts by maintaining nephron progenitors in an undifferentiated state *in vivo* ([@bib2]). KOSR and B27 both contain transferrin and insulin, and these factors are essential for the serum-free culture of fetal kidney explants, where they act synergistically to support growth ([@bib55], [@bib3], [@bib16], [@bib4]). Whether insulin and transferrin are the key FGF-substituting components in KOSR and B27 remains to be determined. Regardless, our identification of KOSR as an inexpensive Stage II medium is a major advance since it lowers the cost per assay, thereby enabling organoid generation at large scales. This breakthrough is a critical prerequisite for efforts to develop kidney organoids as a platform for nephrotoxicity testing and for future clinical applications such as cell replacement therapies ([@bib39]).

With regard to technical complexity, our protocol differs from existing methods by being very simple with few handling steps. For instance, the 3D culture method of [@bib40], which produces organoids that are morphologically similar to ours, involves additional dissociation and centrifugation steps, as well as laborious growth in 96-well plates. Moreover, the most recent method by Taguchi's group requires separate induction of nephron and collecting duct progenitors followed by their co-culture ([@bib50]). In our protocol, the EBs are formed in suspension, thus enabling them to be size-selected and transferred with ease to spinner flasks with minimal effort and time. Perhaps as a result of these fewer handling steps, we observe rapid tubule formation with structures visible by bright-field microscopy as early as day 8, in contrast to other methods that take between 12 and 21 days ([@bib9], [@bib21]).

The organoids made from our protocol develop a well-defined proximal-distal segmentation pattern at day 14 that is comparable with other reports ([@bib53], [@bib40], [@bib15], [@bib51], [@bib6], [@bib27]). A direct comparison with fetal human kidney tissue suggests that our day-14 organoid nephrons correspond to the late capillary loop stage. We anticipated that longer culture times would improve the differentiation of our organoid nephrons. While this appears to be the case for podocytes, we found that the expression of tubule segment markers decreases after day 14 and that overlapping staining of LTL and CDH1 becomes more widespread. Based on observations in the mouse ([@bib7]), it has been suggested that LTL^+^/CDH1^+^ tubules represent mature proximal tubules ([@bib53]). However, in human fetal and adult kidneys we did not observe appreciable overlap with LTL and CDH1, except at a low level in descending limbs in the most mature of the fetal nephrons. While the LTL^+^/CDH1^+^ tubules in the organoids may represent differentiation to a descending limb-like identity, given the reduced marker level and the dysmorphic appearance of some of the tubules at day 26, we favor the interpretation that it represents an aberrant state. In support of this, human distal tubule cells have a tendency to transdifferentiate into proximal tubule cells in culture ([@bib1], [@bib56]). This issue of cell identity is of particular importance to resolve, given that nephrotoxins such as cisplatin have been found to only induce injury in LTL^+^/CDH1^+^ tubules and not LTL^+^-only tubules in kidney organoids ([@bib53]).

The decline in organoid "quality" after day 14 may be related to the fibrotic changes we observed at day 26. We found extensive proliferation of MEIS1/2/3^+^ interstitial cells that co-label with ACTA2, a marker of pro-fibrotic myofibroblasts, and the deposition of collagen-rich extracellular matrix. Renal fibrosis is the common endpoint of end-stage renal failure and is thought to result from a maladaptive wound-healing response ([@bib20]). It is possible that culture beyond day 14 leads to tubular injury, perhaps in response to limitations in the mass transport of oxygen or nutrients into the organoid. While we sieve out large organoids with overt core apoptosis, the smaller organoids may still be undergoing sublethal levels of stress and releasing pro-fibrotic factors ([@bib30]). If diffusion of oxygen/nutrients was responsible we might expect to see the fibrosis restricted to the core; however, it appears throughout the organoid even in peripheral locations. Therefore, there may be other inducers of the fibrosis such as intrinsic changes to the tubules related to aging or altered metabolism in culture. Proliferative changes in the growth of the tubules and interstitium also coincides with the fibrotic phenotype, with both populations dividing at day 14 whereas at day 26, growth is largely restricted to MEIS1/2/3^+^/ACTA2^+^ cells. Large numbers of stromal cells are seen in kidney organoids reported by other methods, suggesting that this issue of interstitial expansion is a widespread problem ([@bib53], [@bib38]). As the pathogenesis of renal fibrosis remains poorly understood and is complicated by the involvement of the immune system in animal models, kidney organoids may provide a useful tool to dissect the non-immune signals involved and for the screening of anti-fibrotic drugs.

To demonstrate the utility of our protocol to study human kidney development, we used gene editing in iPSCs to disrupt the *HNF1B* gene, which is implicated in congenital anomalies of the kidney and urinary tract in 10% of cases in humans ([@bib41]). Kidney organoids made from *HNF1B*^−/−^ iPSCs contained podocytes and GATA3^+^ presumptive collecting ducts but lacked cells with either proximal or distal nephron identities. This phenotype closely resembles the rudimentary nephrons observed in *Hnf1b* conditionally deficient mice, where glomeruli are found connected to the collecting duct system via a short primitive tubule ([@bib17], [@bib34]). Our phenocopy of this result validates the use of kidney organoids as a human-based system to study renal gene function. *Hnf1b*^−/−^ mice (and individuals with heterozygous mutations in *HNF1B*) also develop renal cysts ([@bib13]), but these were not observed in our *HNF1B*^−/−^ kidney organoids even after several weeks in culture (data not shown). This is in contrast to recent work, wherein kidney organoids were used to recapitulate polycystic kidney disease ([@bib12], [@bib15]). Whether additional mutations or altered culture techniques are required to induce the formation of cystic collecting ducts in *HNF1B*^−/−^ kidney organoids remains to be determined.

In summary, our new approach for generating kidney organoids is simple, rapid, scalable, and works robustly for a range of different pluripotent stem cell lines. Our method overcomes many of the drawbacks hampering existing protocols and provides the advance needed in order for kidney organoids to be effectively used for future applications such as drug testing and cell replacement therapies where there is a requirement to generate large amounts of tissue.

Experimental Procedures {#sec4}
=======================

Fetal Human Tissue {#sec4.1}
------------------

Consented, de-identified human fetal tissue from elective terminations was collected following review of the study by the Institutional Review Board at Keck School of Medicine of the University of Southern California. See [Supplemental Information](#app2){ref-type="sec"} for further information.

All experiments were performed with the three iPSC lines described below. For immunostaining, electron microscopy, and qPCR, data are representative of all three lines (unless stated otherwise). Individual stainings and measurements were performed at least in triplicate.

iPSC Lines {#sec4.2}
----------

All work was carried out with the approval of Human Participants Ethics Committees (UAHPEC 8712 and HDEC 17/NTA/204) and biosafety approval (GMO05). BJ RiPS (reprogrammed by RNA) was a gift from Dr. Chad Cowan ([@bib57]). CRL1502 clone C32 (reprogrammed by episomal vectors) was developed in the Wolvetang laboratory ([@bib5]). The MANZ-2-2 line was generated in the Davidson laboratory (see [Supplemental Information](#app2){ref-type="sec"}).

Organoid Formation {#sec4.3}
------------------

Prior to EB formation, iPSCs were cultured on a 10-cm Geltrex-coated dish to 40%--50% confluence at which point discrete colonies have formed. Cells were washed twice with Dulbecco's PBS and incubated with 2 mL of 1 mg/mL dispase for 6 min at 37°C. Cells were washed three times with DBPS, scraped with a cell lifter, resuspended in BPEL plus 8 μM CHIR99021, 3.3 μM Y27632, and 1 mM β-mercaptoethanol, and evenly distributed into ultra-low 6-well attachment plates (Corning). BPEL medium was prepared as described in [@bib43] but with 0.1× ITS-X as per [@bib44]. Half medium change was carried out on day 2 with BPEL supplemented with 8 μM CHIR99021. On day 3, EBs were allowed to sediment in a 50-mL tube and washed twice in DMEM. EBs were returned to the ultra-low 6-well attachment plate and transferred to Stage II culture medium (DMEM, 15% KOSR \[Thermo Fisher\], 1% non-essential amino acids, 1% penicillin/streptomycin, 1% HEPES, 1% GlutaMAX, 0.05% poly(vinyl alcohol), 2.5 μg/mL Plasmocin). Upon tubule formation (days 7--8), organoids were transferred into a 125-mL spinner flask (Corning) in 45 mL of Stage II medium, stirring at 90 rpm, with half medium change every 2 days. Alternatively, organoids were left in the ultra-low 6-well attachment plate and agitated using an orbital shaker ([@bib19]). No quantitative or qualitative differences in organoid number were observed when grown in either spinner flasks or 6-well plates. One milliliter of medium was determined to be the minimum volume for culturing of ∼50 organoids. Therefore, the 6-well plate format is restricted to 900 organoids (with 3 mL of medium per well), whereas a 125-mL spinner flask can be scaled up to a maximum of 6,250 organoids.

Size Filtration and Measurement {#sec4.4}
-------------------------------

Organoids were passed through 200- and 500-μm strainers (pluriStrainer). Whole organoid photos were acquired in bright field on an EVOS XL inverted microscope and analyzed using ImageJ. For efficiency, a random subset of each assay was photographed and counted for tubular versus non-tubular organoids at day 8. For size measurements a whole assay was analyzed.

Reabsorption Assay {#sec4.5}
------------------

20 μg/mL 10-kDa rhodamine-dextran was added to Stage II culture medium for 48 hr. Organoids were washed in Stage II medium for 5 hr before fixation in 4% paraformaldehyde, paraffin embedding, and sectioning.

HNF1B Knockout {#sec4.6}
--------------

Guide RNA (gRNA) pairs targeted to introduce an 89-bp deletion in exon 2 of the *HNF1B* gene were designed using the RGEN, COSMID, and CCtop online tools ([@bib46], [@bib11], [@bib49]). gRNAs were cloned into the pSpCas9(BB)-2A-GFP (Addgene 48138) construct, and knockout efficiencies for gRNA pairs were evaluated in HEK293 cells. Plasmids containing the gRNAs with highest knockout efficiency (gRNA1: 5′-AGG GAG GTG GTC GAT GTC ACC GG-3′; gRNA2: 5′-CCT GGT ACG TCA GAA AGC AAC GA-3′) were introduced into the MANZ-2-2 iPSC line by reverse transfection using *Trans*IT-LT1 (Mirus Bio). 48 hours after transfection, GFP-positive cells were isolated by fluorescence-activated cell sorting and 8,000 cells were plated on a 10-cm Geltrex-coated dish into pre-warmed mTeSR1 plus 5 μM Y27632. Medium was changed daily using conditioned mTeSR1 without Y27632. Single colonies were manually picked when they had reached a suitable size (∼10 days post plating), clonally expanded, and screened for biallelic deletion clones using PCR primers flanking the deleted region ([@bib47]). Homozygote deletions were verified by Sanger sequencing. Clones were expanded, karyotyped, and used for organoid assays. Control experiments were carried out with MANZ-2-2 iPSCs.

See [Supplemental Information](#app2){ref-type="sec"} for additional experimental procedures.
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